Deerfield Management Company is an SEC-registered investment adviser based in New York, NY that reports managing 11 hedge funds on Form ADV. It reports $19.1 billion in regulatory assets under management. Its private funds, of all types, hold $19.2 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +17.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +66.2% from Q3 2025 to Q2 2026, compared with +20.9% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $19.1 billionForm ADV Item 5.F
- Gross assets of private funds
- $19.2 billionAll private fund types, Form ADV
- Hedge funds managed
- 1112 private funds in total
- Employees
- 189Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 157876
- Latest Form ADV
- 07/31/2026Disciplinary disclosures: yes, see SEC record
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +16.2% | +14.8% |
| Q1 2026 | +1.3% | -4.6% |
| Q4 2025 | +23.7% | +2.4% |
| Q3 2025 | +14.2% | +7.8% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 67 share positions ($5,123,201,110) reported by Deerfield Management Company, L.P. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Revolution Medicines Inc8.51%
- Centene Corp Del5.94%
- United Therapeutics Corp Del5.72%
- Praxis Precision Medicines I5.48%
- Genmab A/s4.78%
- Viatris Inc3.78%
- Cogent Biosciences Inc3.72%
- Celcuity Inc3.72%
- Legend Biotech Corp3.16%
- Vera Therapeutics Inc2.73%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Revolution Medicines Inc | $435,972,240 | 8.51% | 2,124,000 | -11.20% |
| Centene Corp Del | $304,450,120 | 5.94% | 4,901,000 | Unchanged |
| United Therapeutics Corp Del | $292,944,650 | 5.72% | 540,598 | +18.29% |
| Praxis Precision Medicines I | $280,556,712 | 5.48% | 963,351 | Unchanged |
| Genmab A/s | $244,908,875 | 4.78% | 6,865,000 | Unchanged |
| Viatris Inc | $193,821,360 | 3.78% | 10,938,000 | -45.87% |
| Cogent Biosciences Inc | $190,743,140 | 3.72% | 5,957,000 | +18.99% |
| Celcuity Inc | $190,662,241 | 3.72% | 2,397,664 | +65.24% |
| Legend Biotech Corp | $161,857,620 | 3.16% | 8,137,638 | Unchanged |
| Vera Therapeutics Inc | $140,099,142 | 2.73% | 4,338,778 | +10.78% |
| Tango Therapeutics Inc | $129,241,000 | 2.52% | 5,180,000 | +23.61% |
| Biocryst Pharmaceuticals Inc | $129,039,430 | 2.52% | 15,490,928 | +2.61% |
| Brookdale SR Living Inc | $126,029,057 | 2.46% | 11,637,032 | Unchanged |
| Biomarin Pharmaceutical Inc | $121,508,760 | 2.37% | 2,025,146 | +51.94% |
| Ionis Pharmaceuticals Inc | $118,798,871 | 2.32% | 2,660,669 | -10.40% |
| Larimar Therapeutics Inc | $113,764,282 | 2.22% | 35,606,974 | Unchanged |
| Newamsterdam Pharma Company | $103,464,916 | 2.02% | 4,254,314 | -0.25% |
| Mineralys Therapeutics Inc | $99,464,540 | 1.94% | 3,958,000 | Unchanged |
| Boston Scientific Corp | $93,211,956 | 1.82% | 2,135,440 | +62.39% |
| Chemed Corp New | $91,922,740 | 1.79% | 182,000 | +506.67% |
| Inspire Med SYS Inc | $89,950,348 | 1.76% | 1,296,862 | Unchanged |
| Bio Rad Labs Inc | $85,388,900 | 1.67% | 226,070 | Unchanged |
| Pharvaris N V | $82,154,800 | 1.60% | 2,590,000 | -23.28% |
| Dianthus Therapeutics Inc | $80,477,700 | 1.57% | 914,000 | -18.78% |
| Ideaya Biosciences Inc | $76,955,260 | 1.50% | 2,003,000 | -26.21% |
| Syndax Pharmaceuticals Inc | $71,062,120 | 1.39% | 3,779,900 | Unchanged |
| Savara Inc | $70,016,040 | 1.37% | 13,569,000 | Unchanged |
| Certara Inc | $69,118,938 | 1.35% | 7,512,928 | Unchanged |
| Acadia Healthcare Company In | $68,573,698 | 1.34% | 2,493,589 | -44.83% |
| Adapthealth Corp | $64,734,397 | 1.26% | 11,477,730 | Unchanged |
| Parabilis Medicines Inc | $60,727,932 | 1.19% | 1,880,704 | Unchanged |
| Xenon Pharmaceuticals Inc | $60,087,734 | 1.17% | 1,615,696 | Unchanged |
| Arrowhead Pharmaceuticals In | $55,178,473 | 1.08% | 843,063 | -39.31% |
| Envista Holdings Corporation | $51,871,047 | 1.01% | 2,210,100 | Unchanged |
| Stoke Therapeutics Inc | $47,411,000 | 0.93% | 1,823,500 | Unchanged |
| Zoetis Inc | $44,132,560 | 0.86% | 632,000 | New |
| Disc Medicine Inc | $43,007,220 | 0.84% | 657,000 | Unchanged |
| Beta Bionics Inc | $36,132,416 | 0.71% | 1,903,710 | +43.78% |
| Structure Therapeutics Inc | $33,959,220 | 0.66% | 1,086,000 | Unchanged |
| Ars Pharmaceuticals Inc | $32,341,430 | 0.63% | 7,503,812 | Unchanged |
| Belite Bio Inc | $32,265,800 | 0.63% | 190,000 | -46.81% |
| Cooper Cos Inc | $31,487,210 | 0.61% | 557,000 | New |
| Blossomhill Therapeutics Inc | $26,953,440 | 0.53% | 1,446,000 | New |
| Odyssey Therapeutics Inc | $23,245,209 | 0.45% | 1,046,139 | Unchanged |
| Tandem Diabetes Care Inc | $22,685,726 | 0.44% | 1,390,909 | New |
| The Oncology Institute Inc | $21,235,529 | 0.41% | 3,360,052 | Unchanged |
| Avalyn Pharmaceuticals Inc | $20,826,190 | 0.41% | 731,000 | Unchanged |
| Alamar Biosciences Inc | $20,442,000 | 0.40% | 600,000 | Unchanged |
| Tyra Biosciences Inc | $16,017,413 | 0.31% | 732,392 | -27.99% |
| Foghorn Therapeutics Inc | $15,687,890 | 0.31% | 4,394,367 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 7 new positions, 12 sold out, 10 increased, 14 reduced and 36 unchanged.
Number of positions (a count, not dollars)
- New positions7
- Increased10
- Unchanged36
- Reduced14
- Sold out12
New positions
| Stock | Value | Shares |
|---|---|---|
| Zoetis Inc | $44,132,560 | 632,000 |
| Cooper Cos Inc | $31,487,210 | 557,000 |
| Blossomhill Therapeutics Inc | $26,953,440 | 1,446,000 |
| Tandem Diabetes Care Inc | $22,685,726 | 1,390,909 |
| Vogenx Inc | $14,487,763 | 635,707 |
| Alignment Healthcare Inc | $9,566,931 | 1,172,418 |
| Electra Therapeutics Inc | $7,875,000 | 700,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Nuvalent Inc | $2,130,183,575 | 17,248,450 |
| Lantheus Hldgs Inc | $83,537,709 | 752,999 |
| Pfizer Inc | $73,203,200 | 3,040,000 |
| Indivior Pharmaceuticals Inc | $67,654,162 | 1,648,895 |
| Caredx Inc | $56,932,113 | 1,997,618 |
| Sionna Therapeutics Inc | $29,953,495 | 680,916 |
| Alnylam Pharmaceuticals Inc | $20,450,473 | 67,935 |
| Kyverna Therapeutics Inc | $17,820,000 | 2,000,000 |
| Spyglass Pharma Inc | $12,243,000 | 550,000 |
| Mobia Med Inc | $8,988,077 | 670,752 |
| Veracyte Inc | $5,931,730 | 101,000 |
| Surrozen Inc | $2,750 | 166,666 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Chemed Corp New | +152,000 | +506.67% | $91,922,740 | 182,000 |
| Celcuity Inc | +946,650 | +65.24% | $190,662,241 | 2,397,664 |
| United Therapeutics Corp Del | +83,598 | +18.29% | $292,944,650 | 540,598 |
| Biomarin Pharmaceutical Inc | +692,310 | +51.94% | $121,508,760 | 2,025,146 |
| Boston Scientific Corp | +820,440 | +62.39% | $93,211,956 | 2,135,440 |
| Cogent Biosciences Inc | +950,896 | +18.99% | $190,743,140 | 5,957,000 |
| Tango Therapeutics Inc | +989,389 | +23.61% | $129,241,000 | 5,180,000 |
| Vera Therapeutics Inc | +422,378 | +10.78% | $140,099,142 | 4,338,778 |
| Beta Bionics Inc | +579,710 | +43.78% | $36,132,416 | 1,903,710 |
| Biocryst Pharmaceuticals Inc | +394,525 | +2.61% | $129,039,430 | 15,490,928 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Viatris Inc | -9,268,170 | -45.87% | $193,821,360 | 10,938,000 |
| Acadia Healthcare Company In | -2,026,411 | -44.83% | $68,573,698 | 2,493,589 |
| Revolution Medicines Inc | -268,000 | -11.20% | $435,972,240 | 2,124,000 |
| Arrowhead Pharmaceuticals In | -545,992 | -39.31% | $55,178,473 | 843,063 |
| Belite Bio Inc | -167,199 | -46.81% | $32,265,800 | 190,000 |
| Ideaya Biosciences Inc | -711,503 | -26.21% | $76,955,260 | 2,003,000 |
| Pharvaris N V | -786,042 | -23.28% | $82,154,800 | 2,590,000 |
| Dianthus Therapeutics Inc | -211,313 | -18.78% | $80,477,700 | 914,000 |
| Monopar Therapeutics Inc | -186,154 | -57.50% | $10,961,875 | 137,591 |
| Ionis Pharmaceuticals Inc | -308,834 | -10.40% | $118,798,871 | 2,660,669 |
| Bridgebio Oncology Therapeut | -1,747,279 | -35.77% | $12,866,485 | 3,138,167 |
| Tyra Biosciences Inc | -284,608 | -27.99% | $16,017,413 | 732,392 |
| Bright Minds Biosciences Inc | -46,705 | -16.50% | $11,772,217 | 236,295 |
| Newamsterdam Pharma Company | -10,475 | -0.25% | $103,464,916 | 4,254,314 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (1)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private equity funds filing Form D (1)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (11)
As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures